Latest Headlines

Latest Headlines

UPDATED: Google joins forces with Dexcom for miniaturized glucose monitor

Google has been inking deals to expand its reach in patient monitoring and wearable health. In its latest foray the company will work with Dexcom to develop cheaper, miniaturized glucose monitors, combining its electronics platform with Dexcom's sensor technology to improve care for patients.

AZ's MedImmune offers up $727M to get its hands on Inovio cancer vaccine

MedImmune on Monday announced a development deal worth up to $727 million--$27 million upfront--to acquire exclusive rights to Inovio Pharmaceuticals' HPV cancer vaccine INO-3112 and to develop additional cancer vaccine candidates.

Aerie to use GrayBug's delivery tech for sustained release of its ophthalmic candidates

Aerie Pharmaceuticals will use GrayBug's microparticle-based technologies to deliver its candidates to the front and back of the eye under a just-announced one-year research collaboration and licensing agreement. In particular Aerie is seeking to add sustained-release capabilities to its arsenal.

Sanofi takes another stab at cancer with Evotec, Apeiron checkpoint partnership

Three days ago Sanofi expanded its tight R&D relationship with Evotec to take on cell-replacement treatments for diabetes. And the pharma giant picked up this morning where it left off, adding an immuno-oncology pact with Evotec that also brings Austria's Apeiron Biologics into the mix.

Local funds behind Mevion Medical's $200M China JV aimed as country's first proton therapy system

U.S.-based proton therapy system maker Mevion Medical Systems has secured as much as $200 million in financing led by two Chinese Investors, HOPU Investments and YuanMing Capital.

A new normal in China for pharmaceutical industry as reforms accumulate?

Second-quarter earnings from nearly all multinationals showed a drop in business in China from double-digit paces in recent years blamed on tough tender and reimbursement policies and domestic competition as well as an economic slowdown.

UPDATED: AstraZeneca offers $727M package to partner with Inovio on immuno-oncology

AstraZeneca's big MedImmune subsidiary has nailed down its third pact in 5 days, inking a collaboration with Inovio Pharmaceuticals on a cancer vaccine designed to generate a tumor-specific T cell response. MedImmune is handing over a $27.5 million upfront and up to $700 million in milestones for the deal while agreeing to also cover the research tab.

HK-based Ally Bridge joins with WI Harper on $10M Cold Genesys Series B

Hong Kong-based Ally Bridge Capital Partners and China-focused WI Harper provided $10 million in Series B funding for U.S.-based onco-immunotherapy biotech Cold Genysys in a deal that builds on a $13.8 million Series A from the same investors a year ago.

Japan's CiRA hopes for iPS cell clinical work as early as this year with stockpile cost advantage

Japan's Center for iPS Cell Research Application (CiRA) of Kyoto University hopes to ramp up clinical tests starting this or early next year with unspecified clinical research projects aimed at finding possible cures for various diseases as academic, clinical and company efforts merge, Nikkei Asian Review reports.

Cardinal scores $1B DOD contract as dealmaking delivers growth

Cardinal Health snagged a $1 billion contract with the U.S. Department of Defense to provide its medical devices for the DOD's military and federal civilian agencies, a feather in the company's cap as it rides high off promising year-end numbers and prepares to close its deal for Johnson & Johnson's Cordis vascular device unit.